Find Relief
with Spravato

In a clinical study lasting four weeks, Spravato improved symptoms of depression in people taking the drug — most notably in the first 24 hours after taking it. In an additional year-long study of those who saw the most dramatic improvements in their symptoms, Spravato continued to improve depression symptoms. During this study, people took an oral antidepressant with either Spravato or a placebo nasal spray. Those who took Spravato were 51% to 70% less likely to relapse back to severe depression than those taking the placebo.

There are no current head-to-head studies comparing the effectiveness of Spravato to IV ketamine infusions. Based on the experience of practitioners using compounded intranasal ketamine vs. IV ketamine infusions, ketamine infusions appear to have a more robust effect in treating depression and can also be individually adjusted to provide the effectiveness you need.

Although it is given as an intranasal spray, the FDA has highly regulated Spravato and requires that the medication either be sent by the pharmacy directly to the practitioner’s office or purchased from the practitioner’s office. The FDA has also required that Spravato be administered in the practitioner’s office with a two-hour post-application monitoring period in the office.

You can check with your insurance provider as to whether Spravato is a covered service for you, both the medication and application in the office /post-application monitoring period. As it is a brand name drug, without insurance, Spravato is quite expensive without insurance.

The current recommended treatment protocol is for twice a week of treatment for the first four weeks, then weekly treatments for weeks five through nine. Thereafter, treatment frequency is once every one to two weeks. Currently, there are no studies of Spravato for longer than a year.